Isomorphic Labs, a DeepMind spinoff focusing on drug discovery, raised $600M led by Thrive to research treatments, including for cancer and immune disorders (Michael J. de la Merced/New York Times)

Michael J. de la Merced / New York Times: Isomorphic Labs, a DeepMind spinoff focusing on drug discovery, raised $600M led by Thrive to research treatments, including for cancer and immune disorders  —  The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital as a backer.

Mar 31, 2025 - 12:46
 0
Isomorphic Labs, a DeepMind spinoff focusing on drug discovery, raised $600M led by Thrive to research treatments, including for cancer and immune disorders (Michael J. de la Merced/New York Times)

Michael J. de la Merced / New York Times:
Isomorphic Labs, a DeepMind spinoff focusing on drug discovery, raised $600M led by Thrive to research treatments, including for cancer and immune disorders  —  The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital as a backer.